CI

At a glance

ClinicalIndex Comparison Record
N/ANot Yet Recruiting· 100 target
Drug / intervention
Market-approved AVNB, OAC and AAD +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06783868
NCT06783868N/ANot Yet Recruiting
CompareCT.gov

Randomized Control Study to Assess the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control vs Routine Medication Therapy in Patients With Recent Stroke: SAVE STROKE Phase II Study

Kansas City Heart Rhythm Research Foundation·observational·Posted Jan 20, 2025·Updated Aug 28, 2025

In Brief

An observational study evaluating Catheter Ablation and Market-approved AVNB, OAC and AAD for Atrial Fibrillation and Stroke. Not yet recruiting, targeting 100 participants across 7 sites.

Detailed Summary

A prospective, non-blinded, multi-center study to assess the impact of early Catheter Ablation (CA) in patients with a new diagnosis of Atrial Fibrillation(AF) at the time of stroke. 100 patients will be enrolled.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Stroke
CountriesUnited States
Collaborators--

Timeline

N/ANot Yet Recruiting
202520262027
First PostedJan 20, 2025
Enrollment StartOct 1, 2025
Primary CompletionJun 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.7 yearsPosted 1.4 years agoPrimary completion in 11 months

Interventions

Catheter Ablationdevice

Catheter Ablation is commonly performed with radiofrequency or cryotherapy to maintain a rhythm control strategy if patients can no longer tolerate their symptoms or are no longer controlled on AVNB or AAD. The procedure leads to significant symptom improvement even though there may be insignificant AF recurrence at one year. At Kansas City Heart Rhythm Institute, CA may be performed with radiofrequency ablation (Tactiflex Ablation Catheter, Abbott Cardiovascular, Minneapolis, MN) or pulsed field ablation (PulseSelectTM, Abbott Cardiovascular or FaraWaveTM, Boston Scientific, Marlborough, MA), performed with EnsiteX (Abbott Cardiovascular) or Carto3 (Biosense Webster, Irvine, CA) mapping software.

Market-approved AVNB, OAC and AADdrug

Used per protocol for the duration of the trial.